# Theranostics

Source: https://nuclide.cc/journals/theranostics-journal/  
Nuclide record `theranostics-journal` (Journal). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A fully free-to-read journal that publishes research combining diagnosis and treatment, including radioactive drugs.

## Summary

Theranostics is a biweekly, fully open-access journal established in 2011 and published by Ivyspring International Publisher. It covers in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, systems biology and translational and personalised medicine — a broad remit that in practice makes it one of the most frequently cited venues for new PET and SPECT radiotracers, radioligand therapy chemistry, and nanomedicine-based theranostic agents.

Articles are published under a CC BY-NC licence and are immediately free to read, with no subscription barrier; the journal states full compliance with NIH public access requirements. It is indexed in Web of Science (Science Citation Index Expanded), MEDLINE/PubMed and Scopus.

According to the journal's own indexing page, its Journal Citation Reports impact factor was 12.4 for the 2024 JCR release, up from 11.556 in the 2022 release; third-party trackers report further increases in more recent JCR cycles, which readers should verify against Clarivate directly given how fast the metric has moved.

## Fields

- Kind: Journal
- Last checked: 2026-09-22
- Tags: journal; open access; theranostics
- Publisher: Ivyspring International Publisher
- Scope: Theranostics: molecular imaging, molecular therapeutics, image-guided therapy, biosensors, nanomedicine and translational/personalised medicine.
- Access: open-access

## Sources

- Theranostics home: https://www.thno.org/
- Theranostics: Index and ranking (impact factor history): https://www.thno.org/indexrank

---
JSON: https://nuclide.cc/api/v1/entities/theranostics-journal.json